Abstract BACKGROUND With metabolic dysfunction-associated fatty liver disease (MAFLD) incidence and prevalence increasing, it is necessary to identify patients with advanced fibrosis (F3-F4 stages). We evaluated the performance of new biomarkers and algorithms for diagnosing advanced fibrosis in an Asian population. METHODS Data from two Asian cohorts (including 851 biopsy-proven MAFLD [578 from Wenzhou, 273 […]
Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD.
March 1, 2022
Metabolism